scholarly journals Ultraconservative, Fertility Sparing Treatment of Bilateral Borderline Ovarian Tumors: A Case Report of a 26-Year-Old, 0-Gravida with an Endometrioid Borderline Ovarian Tumor of the Right Ovary and a Sero-Mucinous Borderline Ovarian Tumor of the Left Ovary and a Review of the Literature

2020 ◽  
Vol Volume 12 ◽  
pp. 601-611
Author(s):  
Stephanie Verta ◽  
Barbara Kipp
Keyword(s):  
Case Report ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Left Ovary ◽  
Borderline Ovarian Tumor ◽  
Review Of The Literature ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing ◽  
The Right ◽  
Endometrioid Borderline Ovarian Tumor

scholarly journals Foam cell formation associated with a borderline ovarian tumor: a case report

2020 ◽  
Vol 18 (2) ◽  
pp. e57-e59
Author(s):  
Jung-Woo Park ◽  
Keyword(s):  
Growth Rate ◽  
Case Report ◽  
Ovarian Tumor ◽  
Foam Cell ◽  
Cell Formation ◽  
Ovarian Tumors ◽  
Foam Cell Formation ◽  
Borderline Ovarian Tumor ◽  
Pathologic Finding ◽  
Borderline Ovarian Tumors

Foam cell formation is a very common pathologic finding in atherosclerosis, often found in some major organs. However, the involvement of the retroperitoneal organs is very rare and foam cell formation associated with borderline ovarian tumor has not been reported. Borderline ovarian tumors are epithelial ovarian tumors with a low growth rate, low potential to invade or metastasize, and excellent prognosis. Still, a rapidly growing borderline ovarian tumor can exert pressure on the retroperitoneal organs. It may cause retroperitoneal irritation and inflammation, and form a mass lesion in adjacent organs. We report the case of a 41-year-old woman with a borderline ovarian tumor and foam cell infiltration.

scholarly journals Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Shuang Zhang ◽  
Shan Yu ◽  
Wenying Hou ◽  
Xiaoying Li ◽  
Chunping Ning ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Menopausal Status ◽  
Area Under The Curve ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Cancer Antigen 125 ◽  
Borderline Ovarian Tumors ◽  
Risk Of Malignancy ◽  
Risk Of Malignancy Index ◽  
Benign Ovarian Tumors

Abstract Background This study aimed to examine the performance of the four risk of malignancy index (RMI) in discriminating borderline ovarian tumors (BOTs) and benign ovarian masses in daily clinical practice. Methods A total of 162 women with BOTs and 379 women with benign ovarian tumors diagnosed at the Second Affiliated Hospital of Harbin Medical University from January 2012 to December 2016 were enrolled in this retrospective study. Also, we classified these patients into serous borderline ovarian tumor (SBOT) and mucinous borderline ovarian tumor (MBOT) subgroup. Preoperative ultrasound findings, cancer antigen 125 (CA125) and menopausal status were reviewed. The area under the curve (AUC) of receiver operator characteristic curves (ROC) and performance indices of RMI I, RMI II, RMI III and RMI IV were calculated and compared for discrimination between benign ovarian tumors and BOTs. Results RMI I had the highest AUC (0.825, 95% CI: 0.790–0.856) among the four RMIs in BOTs group. Similar results were found in SBOT (0.839, 95% CI: 0.804–0.871) and MBOT (0.791, 95% CI: 0.749–0.829) subgroups. RMI I had the highest specificity among the BOTs group (87.6, 95% CI: 83.9–90.7%), SBOT (87.6, 95% CI: 83.9–90.7%) and MBOT group (87.6, 95% CI: 83.9–90.7%). RMI II scored the highest overall in terms of sensitivity among the BOTs group (69.75, 95% CI: 62.1–76.7%), SBOT (74.34, 95% CI: 65.3–82.1%) and MBOT (59.18, 95% CI: 44.2–73.0%) group. Conclusion Compared to other RMIs, RMI I was the best-performed method for differentiation of BOTs from benign ovarian tumors. At the same time, RMI I also performed best in the discrimination SBOT from benign ovarian tumors.

Management of Borderline Ovarian Tumors: Series of Case Report and Review of the Literature

2020 ◽  
Author(s):  
Nicolae Gica ◽  
Laura Mustata ◽  
Radu Botezatu ◽  
Raluca Chirculescu ◽  
Ruxandra Cigaran ◽  
...  
Keyword(s):  
Case Report ◽  
Ovarian Tumors ◽  
Review Of The Literature ◽  
Borderline Ovarian Tumors

Mixed Ovarian Tumor Composed of Brenner Tumor and Adult-Type Granulosa Cell Tumor: A Case Report of a Very Rare Mixed Ovarian Tumor and a Review of the Literature

2017 ◽  
Vol 26 (4) ◽  
pp. 382-387
Author(s):  
Judit Tamás ◽  
Ildikó Vereczkey ◽  
Erika Tóth ◽  
Erzsébet Csernák ◽  
Katalin Purcsi ◽  
...  
Keyword(s):  
Case Report ◽  
Granulosa Cell ◽  
Ovarian Tumor ◽  
Granulosa Cell Tumor ◽  
Cell Tumor ◽  
Ovarian Tumors ◽  
Review Of The Literature ◽  
Adult Type ◽  
Histologic Subtype ◽  
Brenner Tumor

A combination of ovarian tumors with the same histogenetic origin but different histologic subtype is relatively common, whereas a co-occurrence of tumors with different histogenetic origin is rare. We report a case of mixed ovarian tumor composed of Brenner tumor and adult-type granulosa cell tumor, a combination that to the best of our knowledge has not been reported in the literature until now.

scholarly journals Isolated subcutaneous implantation of a borderline ovarian tumor: A case report and review of the literature

2016 ◽  
Vol 7 (2) ◽  
pp. 270 ◽  
Author(s):  
Malgorzata Banys-Paluchowski ◽  
Borsu Yeganeh ◽  
Jutta Luettges ◽  
Achim Maibach ◽  
Ruediger Langenberg ◽  
...  
Keyword(s):  
Case Report ◽  
Ovarian Tumor ◽  
Borderline Ovarian Tumor ◽  
Review Of The Literature ◽  
Subcutaneous Implantation

A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature

2007 ◽  
Vol 17 (5) ◽  
pp. 1143-1147 ◽  
Author(s):  
M. B. Verbruggen ◽  
R. P. Zweemer ◽  
J. M.J. Piek ◽  
G. A. Van Unnik ◽  
P. J. Van Diest ◽  
...  
Keyword(s):  
Loss Of Heterozygosity ◽  
Ovarian Tumor ◽  
Mutant Allele ◽  
Brca2 Gene ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Female Carrier ◽  
Wild Type ◽  
Borderline Ovarian Tumors ◽  
Tumor Spectrum

Germline BRCA1 and BRCA2 mutations highly increase the risk of breast and female adnexal cancer. The role of these genes in the tumorigenesis of other malignancies is still under debate. Borderline ovarian tumors (BOT) are occasionally found in families with a strong history of breast and/or female adnexal cancer with or without proven germline mutations. We investigated whether a BOT arising in a germline BRCA2 mutation carrier could be attributed to this mutation, in which case BOT should be added to the BRCA2 related tumor spectrum. Tumor DNA of a serous borderline ovarian tumor (sBOT) of a 55-year-old female carrier of a pathogenic BRCA2 mutation (6085G>T) was analyzed for loss of heterozygosity (LOH) of BRCA2. The sBOT cells, unexpectedly, revealed loss of the mutant allele of BRCA2, while ovarian stroma cells and peripheral blood lymphocytes contained both wild-type and mutant allele of BRCA2. The finding that no loss of the wild-type BRCA2 allele was found in the tumor tissue but loss of the mutant allele was seen suggests that sBOT are not part of the BRCA2 related tumor spectrum. In the literature BOT's in germline BRCA1 and BRCA2 mutation carriers are described incidentally, while in patients with a BOT a germline BRCA1 or BRCA2 mutation is rarely found. Therefore, we conclude that borderline ovarian tumors are neither part of the BRCA1- nor the BRCA2- related tumor spectrum.

scholarly journals Recurrence of borderline ovarian tumors: a survival analysis

2021 ◽  
Vol 10 (10) ◽  
pp. 3856
Author(s):  
Sahana Punneshetty ◽  
Anitha Thomas ◽  
Dhanya Susan Thomas ◽  
Rachel George Chandy ◽  
Sherin Daniel ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Good Prognosis ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Borderline Ovarian Tumor ◽  
Non Invasive ◽  
Borderline Ovarian Tumors ◽  
Ovarian Epithelial Tumors ◽  
Fertility Sparing ◽  
Reproductive Aged Women

Background: Borderline ovarian tumors are non-invasive tumors that display greater epithelial proliferation and cytological atypia than benign tumors, but less than carcinomas. They may be treated conservatively in young women, however there is a concern for recurrence and progression to frank malignancy. We aimed to study the clinicopathological features of borderline ovarian tumors and their risk of recurrence.Methods: We reviewed the electronic and paper charts of all borderline ovarian tumors operated between January 1, 2001 and December 31, 2019 at a tertiary level teaching hospital in India. Descriptive statistics such as proportions and means were used. A survival analysis was done for recurrence and death.Results: A total of 93 borderline ovarian tumor patients were identified. The most common histology in our study was mucinous 60 (63%) followed by serous 28 (29%). Ninety two (99%) of them were stage I at diagnosis. Microinvasion was present in 27 (26%) of the cases. Out of the 30 fertility sparing operations performed (unilateral salpingo-oophorectomy/cytectomy), 4 (13%) had recurrences and progressed to malignancy. The overall malignancy rate was 4%. There was one mortality secondary to septic shock.Conclusions: Borderline ovarian tumors account for 10-20% of ovarian epithelial tumors and have extremely good prognosis affecting majorly the reproductive aged women. The low recurrence rate and good five year survival rate, at all the stages of the disease enables to incorporate fertility sparing surgeries as part of the staging.

scholarly journals Telomerase Expression Increased the Risk of Borderline Ovarian Tumors

2016 ◽  
Author(s):  
Mila Maidarti
Keyword(s):  
Odds Ratio ◽  
Immunohistochemical Staining ◽  
Ovarian Tumor ◽  
Obstet Gynecol ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Borderline Ovarian Tumors ◽  
Benign Ovarian Tumor ◽  
Benign Ovarian Tumors

Objective: To compare the expression of telomerase in benign ovarian tumors and borderline ovarian tumors. Methods: Thirteen samples of paraffin blocks of ovarian borderline tumors and benign ovarian tumors were taken from patients who underwent surgery from January 2006 to December 2011. In all samples, we performed immunohistochemical staining to the paraffin blocks. Semi quantitative determination of the expression of telomerase is done by an Anatomic Pathology specialist and Gynecologist, which already had the same perception about assessing the standardization sample. We used Fisher’s test to analyze the data. Results: There were significant relationship in the moderate expression of telomerase in the nucleus and cytoplasm between benign and borderline ovarian tumors, with an odds ratio of moderate telomerase expression in the cytoplasm and nucleus of 19.3 (95% CI: 1.4 - 943) and 26 (95% CI : 2.3 - 1211). This means that the risk of borderline ovarian tumors in the expression of moderate telomerase in the cytoplasm was 3.19 times compared to the negative expression, whereas in the nucleus it became 26-fold. There is no significant relationship among menopause, age, and telomerase expression in the nucleus and cytoplasm. Conclusion: There are significant differences in the expression of moderate strength telomerase in nucleus and cytoplasm between benign and borderline ovarian tumors. [Indones J Obstet Gynecol 2013; 37-1: 32-40] Keywords: benign ovarian tumor, borderline ovarian tumor, telomerase expression

Sign in / Sign up

Export Citation Format

Share Document